Grey market tirzepatide at week 11: what the science says

What's this video probably claiming?

Based on the caption and hashtags, @momlifewithjanice is documenting her week 11 experience on tirzepatide 10mg, sourced through what she openly tags as the grey market. The video is almost certainly a progress update: weight lost so far, side effects she's dealt with, maybe a before-and-after visual. The #glp1community format is well-worn at this point, a weekly check-in that functions as both personal diary and informal product endorsement. What it probably is not doing is discussing whether her compound is pharmaceutical-grade, whether her dose was titrated under clinical supervision, or what the FDA has actually said about compounded tirzepatide. That context rarely makes it into the 60-second format, which is exactly why it matters.

What does the science actually show?

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) is the benchmark: at 72 weeks, participants on 15mg tirzepatide lost a mean of 20.9% of body weight versus 3.1% on placebo. The 10mg dose achieved roughly 19.5% mean reduction. Those are remarkable numbers. But they come from a controlled trial with careful dose escalation starting at 2.5mg and titrating every 4 weeks, plus continuous medical monitoring. By week 11 of standard titration, a patient would typically be reaching the 7.5mg or 10mg dose only if they tolerated earlier steps. Jumping to 10mg without that ramp creates meaningfully higher risk of severe nausea, vomiting, and gastroparesis-adjacent symptoms. The efficacy data is real. The protocol behind it matters just as much.

Where does the social media noise diverge from clinical reality?

Several things the #glp1girlies content universe tends to flatten out deserve direct attention. First, compounded tirzepatide is not the same as Zepbound or Mounjaro. The FDA has stated this explicitly. Compounded versions are not FDA-approved, and the agency issued warnings in 2024 about variability in compounded GLP-1 products, including dosing errors and contamination reports. Second, grey market sourcing, meaning outside a licensed prescriber and licensed pharmacy, removes the safety net entirely. There is no guaranteed sterility testing, no verified active pharmaceutical ingredient concentration, and no adverse event reporting chain. Third, week 11 weight loss on social media is almost always the most dramatic phase. The SURMOUNT-1 data shows the curve flattens considerably after week 36. Early results shared online systematically oversample the good weeks.

What should you actually know?

If you're considering tirzepatide for weight management, the clinical evidence for the drug itself is among the strongest in obesity medicine. But the delivery mechanism matters enormously. A 2023 analysis published in Obesity (Tchang et al.) found that patients who self-titrated GLP-1 medications without provider oversight had significantly higher rates of discontinuation due to GI adverse events compared to protocol-adherent patients. The FDA placed compounded tirzepatide on the shortage list removal path in early 2024, meaning compounders are operating in an increasingly contested regulatory space. Getting this drug through a licensed telehealth provider who follows an evidence-based titration schedule is not bureaucratic friction. It is the part of the protocol that explains why the trial results look the way they do. Week 11 enthusiasm is understandable. It does not substitute for informed clinical oversight.